The Roadmap to Rebound
For investors wondering when the "valuation gap" will close, three specific windows in late 2026 and early 2027 will define the stock's trajectory:
-
June 2026: The transition of leadership in the Insurance segment to Aaron Martin will signal a new approach to "margin-first" bidding.
-
October 2026: The release of the 2027 Star Ratings. If Humana shows a return to the 4-star threshold for its major contracts, the stock could see a massive re-rating.
-
Q1 2027 Guidance: This will be the first time management can prove that the 25% membership growth from 2026 has actually started to contribute to the bottom line.
Summary: Humana is a "coiled spring" stock. It is currently suppressed by the 2026 "Star Ratings tax" and the high cost of its own success (membership growth). If it can navigate the 2027 bid cycle with discipline, it is well-positioned to hit its 3% margin commitment by 2028.